MedTrace Logo

Iclusig PMS in CML or Ph+ALL Patients

NCT03709017 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-12-07

No results posted yet for this study

Summary

This is a Post-Marketing Surveillance (PMS) of Iclusig® Tablets in accordance with Korean regulations on Risk Management Plan (RMP). This PMS is to assess safety and effectiveness data after administrating Ponatinib (of Iclusig® Tablets) per approved indication, usage and dosage.

Conditions

  • Chronic Myeloid Leukemia
  • Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Interventions

DRUG

Ponatinib

Iclusig 45mg, 15mg

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-07
Primary Completion
2022-11-29
Completion
2023-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03709017 on ClinicalTrials.gov